Literature DB >> 10450390

Ocular complications with high-dose interferon alpha in chronic active hepatitis.

S Kadayifcilar1, S Boyacioglu, H Kart, M Gursoy, P Aydin.   

Abstract

PURPOSE: Interferon alpha, which is used to treat various systemic disorders, has many reversible side-effects involving various organ systems. In this study, chronic active hepatitis patients undergoing interferon alpha therapy were followed with regard to the ocular side-effects.
METHODS: Thirty-six patients with chronic active hepatitis undergoing subcutaneous interferon alpha therapy for 1 year were enrolled. Complete ocular examination and photographic documentation were performed at baseline of the therapy and monthly thereafter. Fisher's exact chi-squared test and Mann-Whitney U-test were employed in the statistical evaluation of the results.
RESULTS: Trichomegaly was noted in 2 (6%) patients. Fifteen patients (42%) were found to have retinopathy with cotton wool spot formation and splinter haemorrhages.
CONCLUSIONS: These findings emphasise the need to monitor these retinal complications, which may result in loss of vision in patients receiving interferon alpha therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450390     DOI: 10.1038/eye.1999.59

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  14 in total

Review 1.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Yoshihiko Nagase; Yuhtaro Kobayashi; Kiyomi Yasuda; Kazuhiko Koike; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 4.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

5.  Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.

Authors:  Ei Tae Kim; Lee Hoo Kim; Jung Il Lee; Hee Seung Chin
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

Review 6.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 8.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

9.  Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials.

Authors:  Michael McCulloch; Michael Broffman; Jin Gao; John M Colford
Journal:  Am J Public Health       Date:  2002-10       Impact factor: 9.308

10.  Is screening for interferon retinopathy in hepatitis C justified?

Authors:  F M Cuthbertson; M Davies; M McKibbin
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.